|
1
|
Bin JF, Chen LF, Wang Y, Ge H and Chen W:
Bibliometric and visual analysis of global crc circular RNA
research 2015–2023. Front Immunol. 16:15804052025. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tsukanov VV, Vasyutin AV, Kasparov EV and
Tonkikh JL: Is the use of artificial intelligence the main stage
for detecting polyps during colonoscopy? World J Gastroenterol.
31:1065002025. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Saha P, Ravanan P and Talwar P: A
multi-omics exploration of PPARG activation in colon cancer:
Kinases featuring a PPRE sequence within regulatory regions. Biol
Direct. 20:682025. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kamara AA, He S, Joseph Fofanah A, Xu R
and Chen Y: MDPNet: Multiscale dynamic Polyp-focus network for
enhancing medical image polyp segmentation. IEEE Trans Med Imaging.
44:5208–5220. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Araghi M, Soerjomataram I, Jenkins M,
Brierley J, Morris E, Bray F and Arnold M: Global trends in
colorectal cancer mortality: Projections to the year 2035. Int J
Cancer. 144:2992–3000. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ghorbaninezhad F, Nour MA, Farzam OR,
Saeedi H, Vanan AG, Bakhshivand M, Jafarlou M, Hatami-Sadr A and
Baradaran B: The tumor microenvironment and dendritic cells:
Developers of pioneering strategies in colorectal cancer
immunotherapy? Biochim Biophys Acta Rev Cancer. 1880:1892812025.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Steup C, Kennel KB, Neurath MF,
Fichtner-Feigl S and Greten FR: Current and emerging concepts for
systemic treatment of metastatic colorectal cancer. Gut.
74:2070–2095. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hossain MS, Karuniawati H, Jairoun AA,
Urbi Z, Ooi DJ, John A, Lim YC, Kibria KK, Mohiuddin A and Ming LC:
Colorectal cancer: A review of carcinogenesis, global epidemiology,
current challenges, risk factors, preventive and treatment
strategies. Cancers. 14:17322022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nors J, Iversen LH, Erichsen R, Gotschalck
KA and Andersen CL: Incidence of recurrence and time to recurrence
in stage I to III colorectal cancer: A nationwide Danish cohort
study. JAMA Oncol. 10:54–62. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
American Cancer Society, . Cancer Facts
& Figures 2024. Atlanta, GA: American Cancer Society; 2024
|
|
11
|
Sabbatino F, Liguori L, Pepe S and Ferrone
S: Immune checkpoint inhibitors for the treatment of melanoma.
Expert Opin Biol Ther. 22:563–576. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou F, Qiao M and Zhou C: The
cutting-edge progress of immune-checkpoint blockade in lung cancer.
Cell Mol Immunol. 18:279–293. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Makaremi S, Asadzadeh Z, Hemmat N,
Baghbanzadeh A, Sgambato A, Ghorbaninezhad F, Safarpour H,
Argentiero A, Brunetti O, Bernardini R, et al: Immune checkpoint
inhibitors in colorectal cancer: Challenges and future prospects.
Biomedicines. 9:10752021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Emambux S, Tachon G, Junca A and Tougeron
D: Results and challenges of immune checkpoint inhibitors in
colorectal cancer. Expert Opin Biol Ther. 18:561–573. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ros J, Balconi F, Baraibar I, Saoudi
Gonzalez N, Salva F, Tabernero J and Elez E: Advances in immune
checkpoint inhibitor combination strategies for microsatellite
stable colorectal cancer. Front Oncol. 13:11122762023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Trujillo JM, Nuffer W and Smith BA: GLP-1
receptor agonists: An updated review of head-to-head clinical
studies. Ther Adv Endocrinol Metab. 12:20420188219973202021.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y,
Zhang C and Gao J: Glucagon-like peptide-1 receptor: Mechanisms and
advances in therapy. Signal Transduct Target Ther. 9:2342024.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
del Olmo-Garcia MI and Merino-Torres JF:
GLP-1 receptor agonists and cardiovascular disease in patients with
type 2 diabetes. J Diabetes Res. 2018:40204922018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yabut JM and Drucker DJ: Glucagon-like
peptide-1 receptor-based therapeutics for metabolic liver disease.
Endocr Rev. 44:14–32. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Halloum W, Dughem YA, Beier D and Pellesi
L: Glucagon-like peptide-1 (GLP-1) receptor agonists for headache
and pain disorders: A systematic review. J Headache Pain.
25:1122024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gala K, Camilleri M, Goyal M, Ohri A,
Marek G and Ravi K: Glucagon-like Peptide-1 receptor agonist use is
associated with and may lead to esophageal motility abnormalities.
Clin Gastroenterol Hepatol. Nov 8–2025.(Epub ahead of print). doi:
10.1016/j.cgh.2025.11.003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Saha B, Kamalumpundi V and Codipilly DC:
GLP1 and GIP receptor agonists: Effects on the gastrointestinal
tract and management strategies for primary care physicians. Mayo
Clin Proc. Dec 1–2025.(Epub ahead of print). doi:
10.1016/j.mayocp.2025.09.017. View Article : Google Scholar
|
|
23
|
Chen J, Mei A, Wei Y, Li C, Qian H, Min X,
Yang H, Dong L, Rao X and Zhong J: GLP-1 receptor agonist as a
modulator of innate immunity. Front Immunol. 13:9975782022.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
He Y, Xu B, Zhang M, Chen D, Wu S, Gao J,
Liu Y, Zhang Z, Kuang J and Fang Q: Advances in GLP-1 receptor
agonists for pain treatment and their future potential. J Headache
Pain. 26:462025. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Valencia-Rincón E, Rai R, Chandra V and
Wellberg EA: GLP-1 receptor agonists and cancer: Current clinical
evidence and translational opportunities for preclinical research.
J Clin Invest. 135:e1947432025. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rode AK, Buus TB, Mraz V, Al-Jaberi FAH,
Lopez DV, Ford SL, Hennen S, Eliasen IP, Klewe IV, Gharehdaghi L,
et al: Induced human regulatory T cells express the glucagon-like
peptide-1 receptor. Cells. 11:25872022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Paul MS and Ohashi PS: The roles of CD8+ T
cell subsets in antitumor immunity. Trends Cell Biol. 30:695–704.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu YT and Sun ZJ: Turning cold tumors
into hot tumors by improving T-cell infiltration. Theranostics.
11:53652021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vafaei S, Zekiy AO, Khanamir RA, Zaman BA,
Ghayourvahdat A, Azimizonuzi H and Zamani M: Combination therapy
with immune checkpoint inhibitors (ICIs); a new frontier. Cancer
Cell Int. 22:22022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chiang CH, Song J, Chi KY, Chang YC,
Xanthavanij N, Chang Y, Hsia YP, Chiang CH, Ghamari A, Reynolds KL,
et al: Glucagon-like Peptide-1 agonists reduce cardiovascular
events in cancer patients on immune checkpoint inhibitors. Eur J
Cancer. 216:1151702025. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Quagliariello V, Canale ML, Bisceglia I,
Iovine M, Giordano V, Giacobbe I, Scherillo M, Gabrielli D, Maurea
C, Barbato M, et al: Glucagon-like peptide 1 receptor agonists in
Cardio-oncology: Pathophysiology of cardiometabolic outcomes in
cancer patients. Int J Mol Sci. 25:112992024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vignarajah A, Kim S, Albliwi M, Ahn HM,
Izda A, Naffa F, Vigneswaramoorthy N, Barot S and Shah G: Role of
GLP-1 receptor agonists in managing cancer therapy-related cardiac
dysfunction. J Am Heart Assoc. 14:e0409192025. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Borner T, Pataro AM, Doebley SA, Furst CD,
White AD, Gao SX, Chow A, Sanchez-Navarro MJ, Ghidewon MY, Halas
JG, et al: Hypophagia and body weight loss by tirzepatide are
accompanied by fewer GI adverse events compared to semaglutide in
preclinical models. Sci Adv. 11:eadu15892025. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wen Z, Luo D, Wang S, Rong R, Evers BM,
Jia L, Fang Y, Daoud EV, Yang S, Gu Z, et al: Deep Learning-Based
H-Score quantification of Immunohistochemistry-stained images. Mod
Pathol. 37:1003982024. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using Real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Islam MR, Akash S, Rahman MM, Nowrin FT,
Akter T, Shohag S, Rauf A, Aljohani AS and Simal-Gandara J: Colon
cancer and colorectal cancer: Prevention and treatment by potential
natural products. Chem Biol Interact. 368:1101702022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ben Nasr M, Usuelli V, Dellepiane S,
Seelam AJ, Fiorentino TV, D'Addio F, Fiorina E, Xu C, Xie Y,
Balasubramanian HB, et al: Glucagon-like peptide 1 receptor is a T
cell-negative costimulatory molecule. Cell Metab. 36:1302–1319.e12.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wong CK, Yusta B, Koehler JA, Baggio LL,
McLean BA, Matthews D, Seeley RJ and Drucker DJ: Divergent roles
for the gut intraepithelial lymphocyte GLP-1R in control of
metabolism, microbiota, and T cell-induced inflammation. Cell
Metab. 34:1514–1531.e7. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shilyansky JS, Chan CJ, Xiao S,
Gribovskaja-Rupp I, Quelle DE, Howe JR, Dillon JS and Ear PH:
GLP-1R agonist promotes proliferation of neuroendocrine neoplasm
cells expressing GLP-1 receptors. Surgery. 179:1089432025.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shabil M, Khatib MN, Ballal S, Bansal P,
Tomar BS, Ashraf A, Kumar MR, Sinha A, Rawat P, Gaidhane AM, et al:
Risk of hepatocellular carcinoma with Glucagon-like Peptide-1
receptor agonist treatment in patients: A systematic review and
meta-analysis. BMC Endocr Disord. 24:2462024. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Koehler JA, Kain T and Drucker DJ:
Glucagon-like peptide-1 receptor activation inhibits growth and
augments apoptosis in murine CT26 colon cancer cells.
Endocrinology. 152:3362–3372. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tang Y, Wei J, Ge X, Yu C, Lu W, Qian Y,
Yang H, Fu D, Fang Y, Zhou X, et al: Intratumoral injection of
interferon gamma promotes the efficacy of anti-PD1 treatment in
colorectal cancer. Cancer Lett. 588:2167982024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhong FM, Yao FY, Yang YL, Liu J, Li MY,
Jiang JY, Zhang N, Xu YM, Li SQ, Cheng Y, et al: Molecular subtypes
predict therapeutic responses and identifying and validating
diagnostic signatures based on machine learning in chronic myeloid
leukemia. Cancer Cell Int. 23:612023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xie Y, Lv Z, Wang Y, Ma J, Wei X, Zheng G
and Wu J: Study on the efficacy of IFN-γ- and sPD-1-overexpressing
BMSCs in enhancing immune effects for the treatment of lung
adenocarcinoma. Front Immunol. 16:15544672025. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hogg GD, Weinstein AG, Kingston NL, Liu X,
Dres OM, Kang LI, Lander VE, Kao YL, Ahmad F, Knolhoff BL, et al:
Combined Flt3L and CD40 agonism restores dendritic cell-driven T
cell immunity in pancreatic cancer. Sci Immunol. 10:eadp39782025.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Andrews LP, Butler SC, Cui J, Cillo AR,
Cardello C, Liu C, Brunazzi EA, Baessler A, Xie B, Kunning SR, et
al: LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell
exhaustion and hinder autocrine IFN-γ-dependent anti-tumor
immunity. Cell. 187:4355–4372.e22. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhou C, Cheng X and Tu S: Current status
and future perspective of immune checkpoint inhibitors in
colorectal cancer. Cancer Lett. 521:119–129. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sahin IH, Ciombor KK, Diaz LA, Yu J and
Kim R: Immunotherapy for microsatellite stable colorectal cancers:
Challenges and novel therapeutic avenues. Am Soc Clin Oncol Educ
Book. 42:1–12. 2022.PubMed/NCBI
|
|
50
|
Yan W, Qiu L, Yang M, Xu A, Ma M, Yuan Q,
Ma X, Liang W, Li X and Lu Y: CXCL10 mediates CD8+ T cells to
facilitate vessel normalization and improve the efficacy of
cetuximab combined with PD-1 checkpoint inhibitors in colorectal
cancer. Cancer Lett. 567:2162632023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhou W, Qu M, Yue Y, Zhong Z, Nan K, Sun
X, Wu Q, Zhang J, Chen W and Miao C: Acetylcysteine synergizes PD-1
blockers against colorectal cancer progression by promoting TCF1+
PD1+ CD8+ T cell differentiation. Cell Commun Signal. 22:5032024.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhu C, Lai Y, Liu C, Teng L, Zhu Y, Lin X,
Fu X, Lai Q, Liu S, Zhou X and Fang Y: Comprehensively prognostic
and immunological analyses of GLP-1 signaling-related genes in
pan-cancer and validation in colorectal cancer. Front Pharmacol.
15:13872432024. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Alharbi SH: Anti-inflammatory role of
glucagon-like peptide 1 receptor agonists and its clinical
implications. Ther Adv Endocrinol Metab. 15:204201882312223672024.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wong S, Le GH, Dri CE, Teopiz KM and
McIntyre RS: Evaluating biased agonism of glucagon-like peptide-1
(GLP-1) receptors to improve cellular bioenergetics: A systematic
review. Diabetes Obes Metab. 27:6105–6115. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wong CK, Yusta B, Tong JCL, Broichhagen J,
Hodson DJ and Drucker DJ: Reassessment of antibody-based detection
of the murine T cell GLP-1 receptor. Cell Metab. 37:1783–1788.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Pang J, Feng JN, Ling W and Jin T: The
anti-inflammatory feature of glucagon-like peptide-1 and its based
diabetes drugs-Therapeutic potential exploration in lung injury.
Acta Pharm Sin B. 12:4040–4055. 2022. View Article : Google Scholar : PubMed/NCBI
|
